Viking Therapeutics has successfully closed an upsized offering of common stock and convertible senior notes, securing approximately $575 million in gross proceeds. The capital injection significantly bolsters the clinical-stage biopharmaceutical firm's balance sheet as it advances its metabolic and endocrine disorder pipeline.
Viking Therapeutics closed upsized offerings of common stock and convertible senior notes, raising approximately $575 million in gross proceeds, which strengthens its cash position but dilutes existing shareholders.